Merck Collaborates with GlaxoSmithKline on MK-3475
December 18, 2013 at 07:51 AM EST
Merck (NYSE: MRK ) today announced the initiation of a clinical trial to evaluate the combination of the company's investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline's (NYSE:
